C12N 2760/14134
Use of virus or viral component as vaccine
Official title: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2760/14134 (Use of virus or viral component as vaccine) appears on 130 US grants and 219 published applications in this corpus.
Search patents in C12N- Granted patents
- 130
- Published applications
- 219
- Assignees
- 128
- Inventors
- 340
- Latest grant
- 12 May 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2001 | 1 | 0 |
| 2002 | 0 | 1 |
| 2003 | 2 | 3 |
| 2004 | 0 | 4 |
| 2005 | 1 | 4 |
| 2006 | 1 | 5 |
| 2007 | 2 | 2 |
| 2008 | 0 | 2 |
| 2009 | 3 | 3 |
| 2010 | 3 | 9 |
| 2011 | 3 | 5 |
| 2012 | 7 | 5 |
| 2013 | 2 | 7 |
| 2014 | 2 | 7 |
| 2015 | 3 | 7 |
| 2016 | 6 | 14 |
| 2017 | 5 | 16 |
| 2018 | 6 | 19 |
| 2019 | 7 | 11 |
| 2020 | 17 | 20 |
| 2021 | 13 | 18 |
| 2022 | 13 | 19 |
| 2023 | 7 | 9 |
| 2024 | 10 | 18 |
| 2025 | 14 | 7 |
| 2026 | 2 | 4 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Compositions and methods for membrane protein structure determination12 May 2026US 12,624,092 B2The Regents of the University of Michigan
- Recombinant viruses, insect cells and their uses in viral detection and vaccination24 Feb 2026US 12,560,607 B2Academia Sinica
- Systems and methods for the production of human polyclonal antibodies16 Dec 2025US 12,497,443 B2Sab, LLC
- Methods for inducing an immune response via buccal and/or sublingual administration of a vaccine18 Nov 2025US 12,472,145 B2Board of Regents, The University of Texas System
- Immunogenic compositions and uses thereof18 Nov 2025US 12,472,244 B2Board of Regents, The University of Texas System
- Vaccines and methods6 Aug 2026US 2026/0224686 A1Cambridge Enterprise Limited
- Immunogenic ebolavirus fusion proteins and related methods23 Jul 2026US 2026/0207728 A1CZ Biohub SF, LLC
- Systems and methods for the production of human polyclonal antibodies11 Jun 2026US 2026/0159574 A1Sab, LLC
- Thermostable mucosal vaccine compositions and methods12 Feb 2026US 2026/0041757 A1Global Health Solutions LLC
- Replicon Compositions and Methods of Using Same for the Treatment of Diseases11 Sep 2025US 2025/0281602 A1BioNTech SE
Most cited
By later US patents
- Adenovirus vector with multiple expression cassettes110US 6,544,780 B1GenPhar, Inc. · 2003
- Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use102US 7,247,472 B2The Trustees of the University of Pennsylavania · 2007
- Pharmaceutical composition containing a stabilised mRNA optimised for translation in its coding regions75US 10,188,748 B2CureVac AG · 2019
- Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses63US 7,491,508 B2The Trustees of the University of Pennsylvania · 2009
- Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use50US 8,105,574 B2The Trustees of the University of Pennsylvania · 2012